Skin (Neoplasia Melanoma)

Cutaneous melanoma--atypical variants and presentations.
[19575065] Aust Fam Physician 38(7): 476-82 (2009)

Studies of humoral and cell-mediated immunity in human melanoma.
[4130586] Yale J Biol Med 46(5): 681-92 (1973)

Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases.
[11725182] J Neuroophthalmol 21(3): 173-87 (2001)

Pegylated interferon alpha-2b as adjuvant treatment of Stage III malignant melanoma: an evidence-based review.
[21042541] Core Evid 5(-): 39-48 (2010)

Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas.
[17178980] Arch Dermatol 142(12): 1551-8 (2006)

Prevalence of melanoma clinically resembling seborrheic keratosis: analysis of 9204 cases.
[12472343] Arch Dermatol 138(12): 1562-6 (2002)

From melanocyte to metastatic malignant melanoma.
[20936153] Dermatol Res Pract 2010(-): - (2010)

Immunotherapy for advanced melanoma.
[18927541] J Invest Dermatol 128(11): 2596-605 (2008)

Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside.
[18927540] J Invest Dermatol 128(11): 2575-95 (2008)

From UVs to metastases: modeling melanoma initiation and progression in the mouse.
[18787547] J Invest Dermatol 128(10): 2381-91 (2008)

Melanoma, nevogenesis, and stem cell biology.
[18787546] J Invest Dermatol 128(10): 2365-80 (2008)

Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma.
[17159915] J Invest Dermatol 127(4): 900-5 (2007)

Pathways to melanoma development: lessons from the mouse.
[12406321] J Invest Dermatol 119(4): 783-92 (2002)

The role of chemokines in melanoma tumor growth and metastasis.
[12060384] J Invest Dermatol 118(6): 915-22 (2002)

Hedgehog signaling in the murine melanoma microenvironment.
[17762973] Angiogenesis 10(4): 259-67 (2007)

Inhibition of B16 melanoma growth in vivo by retroviral vector-mediated human ribonuclease inhibitor.
[16132620] Angiogenesis 8(1): 73-81 (2005)

Increased expression of VEGF-receptors (FLT-1, KDR, NRP-1) and thrombospondin-1 is associated with glomeruloid microvascular proliferation, an aggressive angiogenic phenotype, in malignant melanoma.
[15166498] Angiogenesis 6(4): 295-301 (2003)

The dark side of lysosome-related organelles: specialization of the endocytic pathway for melanosome biogenesis.
[11929605] Traffic 3(4): 237-48 (2002)

Molecular markers of tumor progression in melanoma.
[19949544] Curr Genomics 10(4): 231-9 (2009)

Excision margins in the treatment of primary cutaneous melanoma: a systematic review of randomized controlled trials comparing narrow vs wide excision.
[12361412] Arch Surg 137(10): 1101-5 (2002)

Advances in the care of the patient with malignant melanoma.
[8998116] Ann Surg 225(1): 15-6 (1997)

Recent advances in the care of the patient with malignant melanoma.
[8998115] Ann Surg 225(1): 1-14 (1997)

Surgical prophylaxis of malignant melanoma.
[2009012] Ann Surg 213(4): 308-14 (1991)

Current management of melanoma.
[327949] Ann Surg 186(1): 1-12 (1977)

Advanced malignant melanoma: immunologic and multimodal therapeutic strategies.
[20224761] J Oncol 2010(-): 689893 (2010)

Medical treatment of uveal melanoma.
[17679486] Tumori 93(3): suppl 27-30 (2007)

Immunotherapy of distant metastatic disease.
[19617297] Ann Oncol 20 Suppl 6(-): vi41-50 (2009)

Small molecules and targeted therapies in distant metastatic disease.
[19617296] Ann Oncol 20 Suppl 6(-): vi35-40 (2009)

Utility of adjuvant systemic therapy in melanoma.
[19617295] Ann Oncol 20 Suppl 6(-): vi30-4 (2009)

Surgery and radiotherapy in the treatment of cutaneous melanoma.
[19617294] Ann Oncol 20 Suppl 6(-): vi22-9 (2009)

Staging of cutaneous melanoma.
[19617293] Ann Oncol 20 Suppl 6(-): vi14-21 (2009)

Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.
[18456782] Ann Oncol 19 Suppl 2(-): ii86-8 (2008)

Malignant melanoma: prevention, early detection, and treatment in the 21st century.
[10986965] CA Cancer J Clin 50(4): 215-36; quiz 237-40 (2000)

Surgical management of primary cutaneous melanoma.
[8673694] CA Cancer J Clin 46(4): 217-24 (1996)

State of the science 60th anniversary review: 60 Years of advances in cutaneous melanoma epidemiology, diagnosis, and treatment, as reported in the journal Cancer.
[18798543] Cancer 113(7 Suppl): 1728-43 (2008)

Adjuvant radiotherapy for cutaneous melanoma.
[18260153] Cancer 112(6): 1189-96 (2008)

Influence of age on survival in childhood spitzoid melanomas.
[17326059] Cancer 109(8): 1579-83 (2007)

Chemotherapy for metastatic melanoma: time for a change?
[17200963] Cancer 109(3): 455-64 (2007)

Molecularly targeted therapy for melanoma: current reality and future options.
[17039502] Cancer 107(10): 2317-27 (2006)

Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma.
[16511841] Cancer 106(7): 1431-42 (2006)

Wide excision without radiation for desmoplastic melanoma.
[16080180] Cancer 104(7): 1462-7 (2005)

Breslow thickness and clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging.
[10649252] Cancer 88(3): 589-95 (2000)

Ultra-late recurrence (15 years or longer) of cutaneous melanoma.
[9191524] Cancer 79(12): 2361-70 (1997)

Limiting the morbidity of inguinal lymphadenectomy for metastatic melanoma.
[19556964] Cancer Control 16(3): 240-7 (2009)

Sentinel lymph node biopsy for melanoma: indications and rationale.
[19556963] Cancer Control 16(3): 234-9 (2009)

Pediatric melanoma: a review.
[19556962] Cancer Control 16(3): 225-33 (2009)

Tumor biomarkers in melanoma.
[19556961] Cancer Control 16(3): 219-24 (2009)

Epigenetics in human melanoma.
[19556960] Cancer Control 16(3): 200-18 (2009)

Treatment options for limited or symptomatic metastatic melanoma.
[18596676] Cancer Control 15(3): 239-47 (2008)

Radiation therapy as primary and adjuvant treatment for local and regional melanoma.
[18596675] Cancer Control 15(3): 233-8 (2008)

Therapy for unresectable recurrent and in-transit extremity melanoma.
[18596674] Cancer Control 15(3): 225-32 (2008)

Surgical management of melanoma in situ on chronically sun-damaged skin.
[18596673] Cancer Control 15(3): 216-24 (2008)

The impact of genomics in understanding human melanoma progression and metastasis.
[18596672] Cancer Control 15(3): 202-15 (2008)

Choices in adjuvant therapy of melanoma.
[16258495] Cancer Control 12(4): 236-41 (2005)

Sentinel node biopsy for thin melanomas: which patients should be considered?
[16258494] Cancer Control 12(4): 230-5 (2005)

Cutaneous melanoma: prognostic factors.
[16258493] Cancer Control 12(4): 223-9 (2005)

Malignant melanoma of the conjunctiva.
[15377990] Cancer Control 11(5): 310-6 (2004)

Choroidal melanoma: natural history and management options.
[15377988] Cancer Control 11(5): 296-303 (2004)

The new melanoma staging system.
[11907461] Cancer Control 9(1): 9-15 (2002)

Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis.
[19318635] J Natl Cancer Inst 101(7): 452-74 (2009)

Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).
[19001147] Oncologist 13 Suppl 4(-): 16-25 (2008)

Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206).
[19001146] Oncologist 13 Suppl 4(-): 10-5 (2008)

Temozolomide for the treatment of metastatic melanoma: a systematic review.
[17914081] Oncologist 12(9): 1114-23 (2007)

Recent advances in melanoma biology.
[15047922] Oncologist 9(2): 182-7 (2004)

Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.
[10794805] Oncologist 5(2): 144-51 (2000)

Melanoma: molecular pathogenesis and emerging target therapies (Review).
[19424565] Int J Oncol 34(6): 1481-9 (2009)

Malignant melanoma: genetics and therapeutics in the genomic era.
[16912270] Genes Dev 20(16): 2149-82 (2006)

On the histological diagnosis and prognosis of malignant melanoma.
[6988460] J Clin Pathol 33(2): 101-24 (1980)

Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria.
[15585738] JAMA 292(22): 2771-6 (2004)

Cutaneous malignant melanoma.
[16610570] Mayo Clin Proc 81(4): 500-7 (2006)

Unusual variants of malignant melanoma.
[16446716] Mod Pathol 19 Suppl 2(-): S41-70 (2006)

The role of interval nodes in sentinel lymph node mapping and dissection for melanoma patients.
[17873127] J Nucl Med 48(10): 1607-13 (2007)

Role of nuclear medicine in the management of cutaneous malignant melanoma.
[16741305] J Nucl Med 47(6): 957-67 (2006)

Sentinel lymph node biopsy in melanoma.
[16455622] J Nucl Med 47(2): 191-5 (2006)

Patterns of lymphatic drainage from the skin in patients with melanoma.
[12679402] J Nucl Med 44(4): 570-82 (2003)

Procedure guideline for lymphoscintigraphy and the use of intraoperative gamma probe for sentinel lymph node localization in melanoma of intermediate thickness 1.0.
[12368382] J Nucl Med 43(10): 1414-8 (2002)

Radioguided sentinel lymph node biopsy in malignant cutaneous melanoma.
[12050328] J Nucl Med 43(6): 811-27 (2002)

Long-term follow-up after uveal melanoma charged particle therapy.
[9440169] Trans Am Ophthalmol Soc 95(-): 171-87; discussion 187-91 (1997)

Risk factors for growth and metastasis of small choroidal melanocytic lesions.
[8719682] Trans Am Ophthalmol Soc 93(-): 259-75; discussion 275-9 (1995)

The ultrastructure of conjunctival melanocytic tumors.
[6398936] Trans Am Ophthalmol Soc 82(-): 599-752 (1984)

Conjunctival melanomas: prognostic factors a review and an analysis of a series.
[7257067] Trans Am Ophthalmol Soc 78(-): 467-502 (1980)

Proton beam radiotherapy in the management of uveal melanoma: Clinical experience in Scotland.
[19668544] Clin Ophthalmol 3(-): 49-55 (2009)

High-frequency ultrasound characteristics of 24 iris and iridociliary melanomas: before and after plaque brachytherapy.
[17698751] Arch Ophthalmol 125(8): 1051-8 (2007)

Transpupillary thermotherapy as an adjunct to ruthenium plaque radiotherapy for choroidal melanoma.
[11167280] Acta Ophthalmol Scand 79(1): 19-22 (2001)

Long-term survival after ruthenium plaque radiotherapy for uveal melanoma. A meta-analysis of studies including 1,066 patients.
[10463412] Acta Ophthalmol Scand 77(4): 414-7 (1999)

[Choroidal melanoma: current therapeutic approaches].
[11941244] J Fr Ophtalmol 25(2): 203-11 (2002)

From the outside in, or the inside out. Resecting uveal melanomas.
[9602612] Br J Ophthalmol 82(3): 209 (1998)

Retinoinvasive malignant melanoma of the uvea.
[9349160] Br J Ophthalmol 81(8): 691-7 (1997)

Molecular pathways supporting the proliferation staging of malignant melanoma (review).
[19639220] Int J Mol Med 24(3): 295-301 (2009)

CT of malignant melanoma in the chest, abdomen, and musculoskeletal system.
[2198632] Radiographics 10(4): 603-20 (1990)

The role of sentinel lymph node biopsy in the management of melanoma.
[17972569] Adv Surg 41(-): 241-56 (2007)

Angiogenesis and melanoma - from basic science to clinical trials.
[22016833] Am J Cancer Res 1(7): 852-68 (2011)

Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects.
[22016836] Am J Cancer Res 1(7): 913-24 (2011)

Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
[20555080] Ann Oncol 21 Suppl 5(-): v194-7 (2010)

Advances in systemic treatment of melanoma.
[20943639] Ann Oncol 21 Suppl 7(-): vii339-44 (2010)

Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.
[19454433] Ann Oncol 20 Suppl 4(-): 129-31 (2009)

Cellular and molecular biology of human melanoma.
[12170758] Cancer Biol Ther 1(1): 14-7 (2002)

Survival and the sentinel lymph node in melanoma.
[19885700] Ann Surg Oncol 17(1): 18-20 (2010)

Understanding signaling cascades in melanoma.
[18086245] Photochem Photobiol 84(2): 289-306 (2008)

Biological functions of melanoma-associated antigens.
[15222021] World J Gastroenterol 10(13): 1849-53 (2004)

Mayo Clinic consensus recommendations for the depth of excision in primary cutaneous melanoma.
[21628616] Mayo Clin Proc 86(6): 522-8 (2011)

Role of PET in the initial staging of cutaneous malignant melanoma: systematic review.
[19011184] Radiology 249(3): 836-44 (2008)

The biology of melanoma prognostic factors.
[20670603] Discov Med 10(50): 87-93 (2010)

Viewing malignant melanoma cells as macrophage-tumor hybrids.
[19262091] Cell Adh Migr 1(1): 2-6 (2007)

Chemotherapy and targeted therapy combinations in advanced melanoma.
[16609060] Clin Cancer Res 12(7 Pt 2): 2366s-2370s (2006)

Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma.
[20086001] Clin Cancer Res 16(3): 1042-8 (2010)

Metabolic approaches to treatment of melanoma.
[19861452] Clin Cancer Res 15(21): 6490-4 (2009)

Integrative genomic analysis of aneuploidy in uveal melanoma.
[18172260] Clin Cancer Res 14(1): 115-22 (2008)

Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety.
[20348274] Oncologist 15(4): 416-27 (2010)

What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?
[19648604] Oncologist 14(8): 848-61 (2009)

BRAF, a target in melanoma: implications for solid tumor drug development.
[20629085] Cancer 116(21): 4902-13 (2010)

Determinants of survival in patients with brain metastases from cutaneous melanoma.
[20372154] Br J Cancer 102(8): 1213-8 (2010)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma.
[19156138] Br J Cancer 100(3): 431-5 (2009)

Technologies for the diagnosis of primary melanoma of the skin.
[17115962] Med J Aust 185(10): 533-4 (2006)

Clinicopathological features of and risk factors for multiple primary melanomas.
[16204664] JAMA 294(13): 1647-54 (2005)

Ultraviolet a light: potential underlying causes of melanoma.
[21062150] Future Oncol 6(10): 1523-6 (2010)

Emerging insights into the molecular pathogenesis of uveal melanoma.
[18922120] Future Oncol 4(5): 629-36 (2008)

Imaging of metastatic melanoma.
[17208677] Cancer Imaging 6(-): 204-8 (2006)

Melanoma: promising new discoveries and treatment modalities for difficult clinical scenarios - part II.
[19556959] Cancer Control 16(3): 196-7 (2009)

Prognosticators of melanoma, the melanoma report, and the sentinel lymph node.
[16446717] Mod Pathol 19 Suppl 2(-): S71-87 (2006)

The Spitzoid lesion: rethinking Spitz tumors, atypical variants, 'Spitzoid melanoma' and risk assessment.
[16446713] Mod Pathol 19 Suppl 2(-): S21-33 (2006)

Grading of atypia in nevi: correlation with melanoma risk.
[12920220] Mod Pathol 16(8): 764-71 (2003)

Atypical mole syndrome and dysplastic nevi: identification of populations at risk for developing melanoma - review article.
[21552679] Clinics (Sao Paulo) 66(3): 493-9 (2011)

IMP3: a diagnostic and prognostic biomarker in malignant melanoma.
[18785801] Expert Rev Mol Diagn 8(5): 557-8 (2008)

The beating heart of melanomas: a minor subset of cancer cells sustains tumor growth.
[21487158] Oncotarget 2(4): 313-20 (2011)

NUAK2: an emerging acral melanoma oncogene.
[21911917] Oncotarget 2(9): 695-704 (2011)

PLX4032 and melanoma: resistance, expectations and uncertainty.
[21417847] Expert Rev Anticancer Ther 11(3): 325-8 (2011)

Testing the divergent pathway hypothesis for melanoma: recent findings and future challenges.
[20469991] Expert Rev Anticancer Ther 10(5): 615-8 (2010)

Optimizing regional infusion treatment strategies for melanoma of the extremities.
[19895244] Expert Rev Anticancer Ther 9(11): 1599-609 (2009)

Killing of human melanoma cells induced by activation of class I interferon-regulated signaling pathways via MDA-7/IL-24.
[18511292] Cytokine 43(1): 34-44 (2008)

IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways.
[20216471] Melanoma Res (): (2010)

Mitotic arrest, apoptosis, and sensitization to chemotherapy of melanomas by methionine deprivation stress.
[16908595] Mol Cancer Res 4(8): 575-89 (2006)

The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells.
[11850799] Oncogene 21(5): 708-18 (2002)

Regulation of mda-7 gene expression during human melanoma differentiation.
[10713678] Oncogene 19(10): 1362-8 (2000)

Down-regulated melanoma differentiation associated gene (mda-7) expression in human melanomas.
[11668478] Int J Cancer 94(1): 54-9 (2001)

Loss of MDA-7 expression with progression of melanoma.
[11844832] J Clin Oncol 20(4): 1069-74 (2002)

Melanoma: what are the gaps in our knowledge.
[18532876] PLoS Med 5(6): e122 (2008)

Perianal melanoma disguised as hemorrhoids: case report and discussion.
[15926652] J Natl Med Assoc 97(5): 726-31 (2005)

Anorectal melanoma. Case report and review of the literature.
[17914500] Rom J Morphol Embryol 48(3): 299-302 (2007)

Melanoma diagnosis by confocal microscopy: promise and pitfalls.
[16193554] J Invest Dermatol 125(3): vii (2005)

Understanding melanoma signaling networks as the basis for molecular targeted therapy.
[19571822] J Invest Dermatol 130(1): 28-37 (2010)

Single-agent interleukin-2 in the treatment of metastatic melanoma.
[17576460] Curr Oncol 14(1): 21-6 (2007)

Temozolomide for the treatment of metastatic melanoma.
[17576461] Curr Oncol 14(1): 27-33 (2007)

Metastatic balloon cell malignant melanoma: a case report and literature review.
[21487528] Int J Clin Exp Pathol 4(3): 315-21 (2011)

Excision margins for primary cutaneous melanoma: updated pooled analysis of randomized controlled trials.
[17875844] Arch Surg 142(9): 885-91; discussion 891-3 (2007)

Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis.
[14680348] Can J Surg 46(6): 419-26 (2003)

FISH as an effective diagnostic tool for the management of challenging melanocytic lesions.
[21834951] Diagn Pathol 6(-): 76 (2011)

Metastatic malignant melanoma in bone marrow with occult primary site--a case report with review of literature.
[17910749] Diagn Pathol 2(-): 38 (2007)

Therapeutic options in cutaneous melanoma: latest developments.
[21957431] Ther Adv Med Oncol 3(5): 245-51 (2011)

Skin diseases with high public health impact. Melanoma.
[17951156] Eur J Dermatol 17(6): 559-62 (2007)

Molecular bases of cutaneous and uveal melanomas.
[21876842] Patholog Res Int 2011(-): 159421 (2011)

The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma.
[19548853] Expert Opin Investig Drugs 18(7): 991-1000 (2009)

RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy.
[22013435] Dermatol Res Pract 2012(-): 354191 (2012)

Smouldering malignant melanoma and metastatic dormancy: an update and review.
[22110487] Dermatol Res Pract 2012(-): 461278 (2012)

miRNAs and Melanoma: How Are They Connected?
[21860617] Dermatol Res Pract 2012(-): 528345 (2012)

Review of diagnostic imaging modalities for the surveillance of melanoma patients.
[21876688] Dermatol Res Pract 2012(-): 941921 (2012)

Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.
[21074063] Semin Oncol 37(5): 473-84 (2010)

Angiogenesis in melanoma.
[18083379] Semin Oncol 34(6): 555-65 (2007)

Melanoma in pediatric, adolescent, and young adult patients.
[19835737] Semin Oncol 36(5): 419-31 (2009)

Mouse models for melanoma: a personal perspective.
[19849715] Exp Dermatol 19(2): 157-64 (2010)

The role of ultraviolet radiation in melanomagenesis.
[20067521] Exp Dermatol 19(2): 81-8 (2010)

Sox proteins in melanocyte development and melanoma.
[20444197] Pigment Cell Melanoma Res 23(4): 496-513 (2010)

Roles of endothelin signaling in melanocyte development and melanoma.
[20128875] Pigment Cell Melanoma Res 23(2): 160-70 (2010)

Hear the Wnt Ror: how melanoma cells adjust to changes in Wnt.
[19708915] Pigment Cell Melanoma Res 22(6): 724-39 (2009)

Treatment of metastatic melanoma: an overview.
[19544689] Oncology (Williston Park) 23(6): 488-96 (2009)

Progress in understanding melanoma propagation.
[20655286] Mol Oncol 4(5): 451-7 (2010)

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.
[20630094] J Transl Med 8(-): 67 (2010)

Galectin-1-mediated biochemical controls of melanoma and glioma aggressive behavior.
[21949569] World J Biol Chem 2(9): 193-201 (2011)

Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma.
[20459375] Curr Mol Med 10(4): 405-12 (2010)

Autotaxin: its role in biology of melanoma cells and as a pharmacological target.
[21423677] Enzyme Res 2011(-): 194857 (2011)

Melanocytes in development and cancer.
[19795394] J Cell Physiol 222(1): 38-41 (2010)

Targeted therapy in melanoma.
[20054438] Biologics 3(-): 475-84 (2009)

Long-term pegylated interferon-alpha and its potential in the treatment of melanoma.
[19707406] Biologics 3(-): 169-82 (2009)

Insulin-like growth factor system and sporadic malignant melanoma.
[21224039] Am J Pathol 178(1): 26-31 (2011)

Targeting BRAF for patients with melanoma.
[21139585] Br J Cancer 104(3): 392-8 (2011)

Releasing the brake on the immune system: ipilimumab in melanoma and other tumors.
[21204754] Cancer Biother Radiopharm 25(6): 601-13 (2010)

Malignant melanoma as a target malignancy for the study of the anti-metastatic properties of the heparins.
[20936327] Cancer Metastasis Rev 29(4): 777-84 (2010)

Pure desmoplastic melanoma: a melanoma with distinctive clinical behavior.
[21107116] Ann Surg 252(6): 1052-7 (2010)

Histologically ambiguous ("borderline") primary cutaneous melanocytic tumors: approaches to patient management including the roles of molecular testing and sentinel lymph node biopsy.
[21128774] Arch Pathol Lab Med 134(12): 1770-7 (2010)

Sentinel lymph nodes in cutaneous melanoma: handling, examination, and clinical repercussion.
[21128773] Arch Pathol Lab Med 134(12): 1764-9 (2010)

Prognostication in thin cutaneous melanomas.
[21128772] Arch Pathol Lab Med 134(12): 1758-63 (2010)

Cellular heterogeneity in vertical growth phase melanoma.
[21128771] Arch Pathol Lab Med 134(12): 1750-7 (2010)

Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells.
[21128770] Arch Pathol Lab Med 134(12): 1740-9 (2010)

Malignant melanoma (metastatic).
[21418691] Clin Evid (Online) 2010(): (2010)

Fluorescence in situ hybridization, a diagnostic aid in ambiguous melanocytic tumors: European study of 113 cases.
[21151100] Mod Pathol 24(5): 613-23 (2011)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Skin (Neoplasia Melanoma).php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Skin (Neoplasia Melanoma).php on line 92